查看購物車
  • Simplified Chinese
  • English
  • Japanese
全球腹膜透析市場：按產品、模式、適應症、最終用戶、地區分類 - 2029 年預測
市場調查報告書
商品編碼
1566247

全球腹膜透析市場：按產品、模式、適應症、最終用戶、地區分類 - 2029 年預測

Peritoneal Dialysis Market by Offering (Peritoneal Dialysis Solution Bags, Machines), Modality (Continuous Ambulatory Peritoneal Dialysis Center(CAPD)), Disease Indication (End-Stage Renal Disease), End User (Hospitals) - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 253 Pages | 訂單完成後即時交付

價格

腹膜透析 (PD) 市場規模預計將從 2024 年的 95.8 億美元增至 2029 年的 127 億美元，預測期內複合年成長率為 5.8%。

由於許多國家有利的醫療政策和家庭透析治療治療的報銷，新興市場獲得腹膜透析的機會大大增加。在大多數情況下，美國、加拿大和其他幾個歐洲國家的政策承認腹膜透析比血液透析機具有更高的成本效益和對患者的益處。這些政策透過報銷與腹膜透析相關的大部分治療費用，減少了與治療費用相關的障礙。這使得 PD 成為一種更便宜、更容易獲得的治療方法，報銷系統鼓勵醫療保健專業人員向那些更喜歡在家管理治療的患者推薦 PD，因為它具有靈活性和實用性。例如，在美國，醫療保險的 ESRD 計劃可報銷並促進家庭透析治療的採用。同樣，其他新興市場也支持和鼓勵家庭透析治療家庭透析治療，因為它可以減少住院次數、改善病患治療效果並減輕醫療機構的負擔。家庭透析治療帶來的經濟支持是老年和臥床患者可以透過維持身體活動和更好地照顧自己過上更好的生活的原因。

調查範圍
調查年份 2022-2029
基準年 2023年
預測期 2024-2029
考慮單位 金額（百萬美元）
按細分市場 按提供方式、按疾病適應症、按最終用戶、按地區
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東/非洲、海灣合作理事會

腹膜透析液袋比機器便宜，因為它們不依賴昂貴的技術或維護。這使得腹膜透析袋對於患者和醫療保健系統來說非常便宜，並且其製造和分銷成本使每個人都可以負擔得起，尤其是在醫療保健預算嚴重受限的國家。溶液袋還減少了對昂貴設備和員工培訓的需求，從而降低了整體處理成本。這使得溶液袋作為資源匱乏地區的治療選擇更具吸引力，可以讓更多患者接受所需的透析。

CAPD 用品（尤其是溶液袋）的日益普及導致了它們的引入，特別是在開發中國家。由於 CAPD 僅需要基本消耗品（例如用於所有形式的透析治療的溶液袋），因此即使在醫療資源非常匱乏的地區，它也比昂貴的機器更容易分配和部署。因此，它是一種在實踐中為資源匱乏地區的患者提供的更具成本效益且易於使用的透析形式。醫院設施的易用性和最小化進一步增加了 CAPD 的盛行率，並增加了全球貧困地區獲得透析護理的機會。

大多數醫療保健系統正在推廣家庭透析治療方案，以減少因末期腎功能衰竭(ESRD) 而去醫院就診的幾率，並節省後續的整體醫療費用。透過實施居家腹膜透析，醫療機構可以減少現場透析的需求，節省醫院容量，並最大限度地減少對設施和工作人員的干擾。家庭透析治療還可以讓患者更好地掌控自己的治療，進而改善患者的生活。此外，家庭透析治療的優點是，由於節省了運輸成本，非常經濟，不易受到感染疾病，並且可以促進護理的連續性，使其成為衛生系統有吸引力的選擇。

該報告研究了全球腹膜透析市場，包括按產品、模式、適應症、最終用戶、地區和參與市場的公司概況分類的趨勢。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第 4 章重要考察

第5章市場概況

  • 介紹
  • 市場動態
  • 產業動態
  • 技術分析
  • 供應鏈分析
  • 價值鏈分析
  • 貿易分析
  • 波特五力分析
  • 監管分析
  • 專利分析
  • 價格分析
  • 2024-2025年重大會議和活動
  • 主要相關人員和採購標準
  • 生態系分析
  • 鄰近市場分析
  • 案例研究分析
  • 生成式人工智慧對腹膜透析市場的影響
  • 未滿足的需求和最終用戶的期望
  • 影響客戶業務的趨勢/干擾
  • 投資金籌措場景
  • 程式資料分析

第6章 腹膜透析市場（依產品分類）

  • 介紹
  • 腹膜透析產品
  • 腹膜透析服務

第7章 腹膜透析市場（依方式）

  • 介紹
  • 連續性攜帶式腹膜透析（CAPD）
  • 自動腹膜透析（APD）

第8章 腹膜透析市場（按適應症）

  • 介紹
  • 末期腎病
  • 急性腎損傷
  • 其他

第9章腹膜透析市場（按最終用戶）

  • 介紹
  • 居家照護
  • 醫院及獨立透析中心
  • 其他

第10章 腹膜透析市場（分地區）

  • 介紹
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲
  • 海灣合作理事會國家

第11章競爭格局

  • 概述
  • 主要參與企業的策略/秘密
  • 2019-2023年收益分析
  • 2023 年市場佔有率分析
  • 企業評估矩陣：主要參與企業，2023
  • 企業評估矩陣：Start-Ups/小型企業，2023 年
  • 公司評價及財務指標
  • 競爭場景
  • 品牌/產品比較
  • 腹膜透析市場：研發費用

第12章 公司簡介

  • 主要參與企業
    • FRESENIUS MEDICAL CARE AG
    • BAXTER INTERNATIONAL INC.
    • MEDTRONIC PLC
    • DAVITA INC.
    • BECTON, DICKINSON AND COMPANY
    • TERUMO CORPORATION
    • UTAH MEDICAL PRODUCTS, INC.
    • DIAVERUM AB
    • MEDIONICS
    • NEWSOL TECHNOLOGIES INC.
    • APOLLO DIALYSIS PVT. LTD.
    • US RENAL CARE, INC.
    • NORTHWEST KIDNEY CENTERS
    • RELAVO
    • MITRA INDUSTRIES PVT. LTD.
  • 其他公司
    • JMS CO., LTD.
    • AMECATH
    • POLYMEDICURE
    • HUAREN PHARMACEUTICAL
    • AWAK TECHNOLOGIES
    • INNOVATIVE RENAL CARE
    • ROMSONS
    • SSEM MTHEMBU MEDICAL（PTY）LTD.
    • RENAX BIOMEDICAL TECHNOLOGY CO., LTD.
    • ADVIN HEALTH CARE

第13章附錄

Product Code: MD 9149

The peritoneal dialysis market is projected to reach USD 12.70 Billion by 2029 from USD 9.58 Billion in 2024 at a CAGR of 5.8% during the forecast period. Favorable healthcare policies in developed markets have highly increased access to peritoneal dialysis since many now offer reimbursements for home-based dialysis treatments. In most cases, the United States, Canada, and several others in Europe have come up with policies that acknowledge the cost-effectiveness and better benefits for patients through peritoneal dialysis over in-center hemodialysis. Such policies reduce the barriers associated with the cost of treatment by establishing reimbursement coverage for a significant portion of the PD-associated treatment costs. This could make PD a much more affordable and accessible form of therapy for patients, and reimbursement programs promote the practice of healthcare providers to recommend PD due to its flexibility and practicality, also for those preferring home management of treatment. For instance, in the United States, Medicare's ESRD program encourages wider adoption by providing reimbursements for home dialysis. Likewise, other developed markets also are following and encouraging home dialysis since it reduces hospital admissions, improves patient outcomes, and reduces burdens on the healthcare facilities. The financial support that comes with PD has become a reason for the aged and bedridden patients who have been able to live better as a result of reduced immobilization and enhanced personal care.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD Million)
SegmentsBy Offering, Modality, Disease Indication, End User and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC

"The peritoneal solution bags segment is accounted for the largest share of peritoneal dialysis market."

Peritoneal dialysis solution bags are less expensive than machines because they are not reliant upon pricey technology and maintenance. Because of this, these bags are very inexpensive for patients and healthcare systems, whose production and distribution costs make it possible to sell these bags at prices within everyone's reach, especially in countries that have tightly constrained health care budgets. Solution bags also reduce the requirement for costly equipment and training of the staff, thereby reducing the overall cost of treatment. This adds to the attractiveness of solution bags as a treatment option for a larger number of patients in resource-poor settings for access to necessary dialysis.

"Continuous Ambulatory Peritoneal Dialysis (CAPD) segment holds the largest market share of peritoneal dialysis market."

The increased coverage of CAPD supplies, especially the solution bags, has stimulated its adoption, especially in developing countries. CAPD, being any form of dialysis treatment, requires only basic supplies, like solution bags, and hence is much simpler to distribute and implement in areas with very poor healthcare resources than expensive machinery. Therefore, it is more cost-effective and accessible to patients in low-resource settings as a practically offered form of dialysis. Ease of use and minimization of the use of hospital facilities further increase the adoption rate of CAPD, thereby increasing access to dialysis care in underprivileged areas globally.

"End-stage renal disease segment holds the largest market share in the global peritoneal dialysis market and expected to grow at the highest CAGR during the forecast period"

Most healthcare systems promote home dialysis options to decrease the prevalence of hospital visits attributed to end-stage renal disease (ESRD), which subsequently saves the overall cost of healthcare. Health care providers would benefit from home peritoneal dialysis by reducing the need for in-center dialysis, thus saving hospital facility capacities and minimizing the problems it poses both to facilities and personnel. Home dialysis will also improve patients' lives as they assume control over their treatment. An added advantage of home-based PD is that it is very economical since it saves transportation costs, it minimizes the susceptibility to infection, and encourages continuity of care, which makes it an attractive modality for health care systems.

"Home care setttings segment accounted for the largest market share in the global peritoneal dialysis market and expected to grow at the highest CAGR during the forecast period."

Portable and user-friendly dialysis equipment have further improved the safety and ease of treatment in the home setting for patients. Modern peritoneal dialysis machines are well designed with intuitive interfaces, automation, and compact size, making them devices that patients can use with relative ease, without relying so much on medical knowledge. Thus, independent and comfortable home-based dialysis has reduced a patient's dependence on healthcare professionals. Safety measures have upgraded with live monitoring and automatic alarms that enhanced outcomes best dealt with early before dangers occur. In those innovations, patient confidence in handling their care improved, while the treatment compliance was generally enhanced.

"North America to witness the substantial growth rate during the forecast period."

The peritoneal dialysis market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC Countries based on the region type. In 2023, the Asia Pacific region is projected to exhibit the highest CAGR during the forecast period. However, North America accounts for the largest market share of the peritoneal dialysis market in 2023. North America is the largest regional market for global peritoneal dialysis, and this is partly because healthcare providers in this region have been trained specifically to manage this treatment. This places them in a better position to ensure that patients requiring the treatment receive a holistic education on how to carry out procedures safely and effectively at home. Moreover, these professionals provide timely interventions through effective monitoring, thus making the outcomes better as well as complications as low as possible. Specialized training programs and ongoing professional development in the region further underpin quality care. Such professionalism among healthcare professionals has indeed contributed to success in the introduction and spread of peritoneal dialysis in North America.

A breakdown of the primary participants (supply-side) for the peritoneal dialysis market referred to for this report is provided below:

  • By Company Type: Tier 1-45%, Tier 2-30%, and Tier 3-25%
  • By Designation: C-level-35%, Director Level-25%, and Others-40%
  • By Region: North America-40%, Europe-20%, Asia Pacific-25%, Latin America- 10%, and Middle East and Africa- 3% and GCC Countries- 2%

Prominent players in this market include Baxter International Inc. (US), Fresenius Medical Care AG (Germany), Medtronic plc (Ireland), Davita Inc. (US), Becton, Dickinson and Company (US), Utah Medical Products, Inc. (US), Terumo Corporation (Japan), Diaverum AB (Sweden), Medionics (Canada), Newsol Technologies (Canada), Apollo Dialysis Pvt Ltd (India), U.S. Renal Care, Inc. (US), Northwest Kidney Centers (US), Relavo (US), Mitra Industries Pvt Ltd (India), JMS Co., Ltd. (Japan), AMECATH (Egypt), Polymedicure (India), Huaren Pharmaceutical (China), AWAK Technologies (Singapore), Innovative Renal Care (US), Romsons (India), SSEM Mthembu Medical (Pty) Ltd (South Africa), Renax Biomedical Technology Co., Ltd (China), and Advin Health Care (India).

Research Coverage:

The market study covers the peritoneal dialysis market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by offering, modality, disease indication, end user and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

  • Analysis of Market Dynamics: Drivers (rising prevalence of chronic kidney diseases, growing prevalence of diabetes and hypertension, and technological advancements and increased investment in R&D) restraints (underutilization of peritoneal dialysis in low-income and lower-middle-income countries (LLMICs)) opportunities (increasing growth opportunities in emerging economies, and surge in demand for home dialysis treatment), and challenges (growing incidence of treated kidney failure, and shortage of skilled nephrologists in low-income and lower-middle-income countries (LLMICs))
  • Services/Innovations: Detailed insights on upcoming technologies, research & development activities, and new product launches in the peritoneal dialysis market.
  • Market Development: Comprehensive information on the lucrative emerging markets, components, demographics, end-user, and region.
  • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the peritoneal dialysis market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the peritoneal dialysis market like Baxter International Inc. (US), Fresenius Medical Care AG (Germany), Medtronic plc (Ireland), Davita Inc. (US), Becton, Dickinson and Company (US).

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 IMPACT OF AI/GEN AI

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
    • 2.2.2 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS
    • 2.2.3 USAGE-BASED MARKET ESTIMATION
    • 2.2.4 PRIMARY RESEARCH VALIDATION
  • 2.3 GROWTH FORECAST ESTIMATION
  • 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RISK ASSESSMENT
  • 2.7 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 PERITONEAL DIALYSIS MARKET OVERVIEW
  • 4.2 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY OFFERING (2023)
  • 4.3 PERITONEAL DIALYSIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.4 REGIONAL MIX: PERITONEAL DIALYSIS MARKET (2024-2029)
  • 4.5 PERITONEAL DIALYSIS MARKET: DEVELOPED VS. DEVELOPING ECONOMIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising prevalence of chronic kidney diseases
      • 5.2.1.2 Growing prevalence of diabetes and hypertension
      • 5.2.1.3 Technological advancements and increased investment in R&D
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Underutilization of peritoneal dialysis in low-income and lower-middle-income countries (LLMICs)
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increasing growth opportunities in emerging economies
      • 5.2.3.2 Surge in demand for home dialysis treatment
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Shortage of skilled nephrologists in low-income and lower-middle-income countries (LLMICs)
      • 5.2.4.2 High risk of peritonitis as a barrier to peritoneal dialysis adoption
  • 5.3 INDUSTRY TRENDS
    • 5.3.1 INCREASED ADOPTION OF HOME-BASED TREATMENTS
    • 5.3.2 RISING INCIDENCE OF CHRONIC KIDNEY DISEASE (CKD)
  • 5.4 TECHNOLOGY ANALYSIS
    • 5.4.1 KEY TECHNOLOGIES
      • 5.4.1.1 Automated peritoneal dialysis (APD) machines
    • 5.4.2 COMPLEMENTARY TECHNOLOGIES
      • 5.4.2.1 Remote monitoring systems
    • 5.4.3 ADJACENT TECHNOLOGIES
      • 5.4.3.1 Wearable technology
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 TRADE ANALYSIS
    • 5.7.1 TRADE ANALYSIS FOR PERITONEAL DIALYSIS MACHINES, SOLUTION BAGS, CATHETERS, AND TRANSFER SETS (HS CODE 9018)
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF SUPPLIERS
    • 5.8.4 BARGAINING POWER OF BUYERS
    • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.9 REGULATORY ANALYSIS
    • 5.9.1 REGULATORY LANDSCAPE
      • 5.9.1.1 North America
        • 5.9.1.1.1 US
        • 5.9.1.1.2 Canada
      • 5.9.1.2 Europe
      • 5.9.1.3 Asia Pacific
        • 5.9.1.3.1 India
        • 5.9.1.3.2 China
        • 5.9.1.3.3 Japan
        • 5.9.1.3.4 South Korea
      • 5.9.1.4 Latin America
        • 5.9.1.4.1 Brazil
        • 5.9.1.4.2 Mexico
      • 5.9.1.5 Middle East
      • 5.9.1.6 Africa
    • 5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10 PATENT ANALYSIS
    • 5.10.1 PATENT PUBLICATION TRENDS FOR PERITONEAL DIALYSIS MARKET
    • 5.10.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.11 PRICING ANALYSIS
    • 5.11.1 AVERAGE SELLING PRICE OF PERITONEAL DIALYSIS PRODUCTS AND CONSUMABLES, BY KEY PLAYER (2023)
  • 5.12 KEY CONFERENCES & EVENTS, 2024-2025
  • 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.13.2 KEY BUYING CRITERIA
  • 5.14 ECOSYSTEM ANALYSIS
  • 5.15 ADJACENT MARKET ANALYSIS
    • 5.15.1 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET
    • 5.15.2 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
  • 5.16 CASE STUDY ANALYSIS
  • 5.17 IMPACT OF GENERATIVE AI ON PERITONEAL DIALYSIS MARKET
  • 5.18 UNMET NEEDS AND END-USER EXPECTATIONS
  • 5.19 TRENDS/DISRUPTIONS AFFECTING CUSTOMERS' BUSINESSES
  • 5.20 INVESTMENT & FUNDING SCENARIO
  • 5.21 PROCEDURE DATA ANALYSIS
    • 5.21.1 PREVALENCE DATA FOR TREATED KIDNEY FAILURE

6 PERITONEAL DIALYSIS MARKET, BY OFFERING

  • 6.1 INTRODUCTION
  • 6.2 PERITONEAL DIALYSIS PRODUCTS
    • 6.2.1 PERITONEAL DIALYSIS SOLUTION BAGS
      • 6.2.1.1 High demand for solutions to boost segmental growth
    • 6.2.2 PERITONEAL DIALYSIS MACHINES
      • 6.2.2.1 Rising prevalence of chronic diseases in emerging economies to boost adoption
    • 6.2.3 PERITONEAL DIALYSIS CATHETERS
      • 6.2.3.1 Favorable reimbursement policies to support market growth
    • 6.2.4 PERITONEAL DIALYSIS TRANSFER SETS
      • 6.2.4.1 Product recalls to limit market growth
    • 6.2.5 OTHER PERITONEAL DIALYSIS PRODUCTS
  • 6.3 PERITONEAL DIALYSIS SERVICES
    • 6.3.1 BETTER PRIVACY AND INCREASED COMFORT OF AT-HOME DIALYSIS TREATMENT TO DRIVE MARKET

7 PERITONEAL DIALYSIS MARKET, BY MODALITY

  • 7.1 INTRODUCTION
  • 7.2 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD)
    • 7.2.1 SUPERIOR CLEARANCE OF HIGH-MOLECULAR-WEIGHT SUBSTANCES TO DRIVE MARKET
  • 7.3 AUTOMATED PERITONEAL DIALYSIS (APD)
    • 7.3.1 RISK OF RAPID DECLINE IN RESIDUAL RENAL FUNCTIONS TO LIMIT ADOPTION

8 PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION

  • 8.1 INTRODUCTION
  • 8.2 END-STAGE RENAL DISEASE
    • 8.2.1 GROWING GERIATRIC POPULATION AND INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET
  • 8.3 ACUTE KIDNEY INJURY
    • 8.3.1 INCREASING HOSPITALIZATIONS TO PROPEL MARKET GROWTH
  • 8.4 OTHER DISEASES

9 PERITONEAL DIALYSIS MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 HOME CARE SETTINGS
    • 9.2.1 LOWER COST AND SHORTER HOSPITAL STAYS TO AID MARKET GROWTH
  • 9.3 HOSPITALS & INDEPENDENT DIALYSIS CENTERS
    • 9.3.1 IMPROVED FACILITIES AND INCREASED GOVERNMENT SUPPORT TO DRIVE MARKET
  • 9.4 OTHER END USERS

10 PERITONEAL DIALYSIS MARKET, BY REGION

  • 10.1 INTRODUCTION
    • 10.1.1 PERITONEAL DIALYSIS PREVALENCE DATA
    • 10.1.2 PERITONEAL DIALYSIS PROCEDURE DATA
  • 10.2 NORTH AMERICA
    • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 10.2.2 US
      • 10.2.2.1 US to account for largest market share during study period
    • 10.2.3 CANADA
      • 10.2.3.1 Shortage of dialysis facilities and increased treatment cost to limit market
  • 10.3 EUROPE
    • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 10.3.2 GERMANY
      • 10.3.2.1 Rising number of end-stage renal disease (ESRD) patients to boost market growth
    • 10.3.3 UK
      • 10.3.3.1 Increased number of new dialysis centers and technological advancements to support market growth
    • 10.3.4 FRANCE
      • 10.3.4.1 Low cost of peritoneal dialysis and consistent reimbursement policies to drive market growth
    • 10.3.5 ITALY
      • 10.3.5.1 Increasing research activities and growing patient population with acute renal failure to augment market growth
    • 10.3.6 SPAIN
      • 10.3.6.1 Favorable reimbursement scenario to boost market growth
    • 10.3.7 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 10.4.2 JAPAN
      • 10.4.2.1 High prevalence of end-stage renal disease (ESRD) and large geriatric population to support market growth
    • 10.4.3 CHINA
      • 10.4.3.1 Increasing prevalence of diabetes and hypertension to drive market
    • 10.4.4 INDIA
      • 10.4.4.1 Favorable government initiatives and high prevalence of kidney disease to fuel market growth
    • 10.4.5 AUSTRALIA
      • 10.4.5.1 Increasing government initiatives about renal care to support market growth
    • 10.4.6 SOUTH KOREA
      • 10.4.6.1 Growing geriatric population with chronic kidney disease to propel market growth
    • 10.4.7 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 10.5.2 BRAZIL
      • 10.5.2.1 Brazil to account for largest share of Latin American market during forecast period
    • 10.5.3 MEXICO
      • 10.5.3.1 Increasing patient population and growing middle class population to boost market growth
    • 10.5.4 REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 GROWING DEMAND FOR CONVENIENT AND ACCESSIBLE RENAL CARE TO PROPEL GROWTH
    • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.7 GCC COUNTRIES
    • 10.7.1 HIGHER DISPOSABLE INCOME AND INCREASED GOVERNMENT HEALTHCARE EXPENDITURE TO PROPEL MARKET GROWTH
    • 10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN PERITONEAL DIALYSIS MARKET
  • 11.3 REVENUE ANALYSIS, 2019-2023
  • 11.4 MARKET SHARE ANALYSIS, 2023
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 11.5.5.1 Company footprint
      • 11.5.5.2 Offering footprint
      • 11.5.5.3 Modality footprint
      • 11.5.5.4 Disease indication footprint
      • 11.5.5.5 End-user footprint
      • 11.5.5.6 Region footprint
  • 11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 RESPONSIVE COMPANIES
    • 11.6.3 DYNAMIC COMPANIES
    • 11.6.4 STARTING BLOCKS
    • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 11.7 COMPANY VALUATION & FINANCIAL METRICS
  • 11.8 COMPETITIVE SCENARIO
    • 11.8.1 PRODUCT APPROVALS
    • 11.8.2 DEALS
    • 11.8.3 EXPANSIONS
  • 11.9 BRAND/PRODUCT COMPARISON
  • 11.10 PERITONEAL DIALYSIS MARKET: R&D EXPENDITURE

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
    • 12.1.1 FRESENIUS MEDICAL CARE AG
      • 12.1.1.1 Business overview
      • 12.1.1.2 Products & services offered
      • 12.1.1.3 Recent developments
        • 12.1.1.3.1 Deals
      • 12.1.1.4 MnM view
        • 12.1.1.4.1 Right to win
        • 12.1.1.4.2 Strategic choices
        • 12.1.1.4.3 Weaknesses & competitive threats
    • 12.1.2 BAXTER INTERNATIONAL INC.
      • 12.1.2.1 Business overview
      • 12.1.2.2 Products & services offered
      • 12.1.2.3 Recent developments
        • 12.1.2.3.1 Deals
      • 12.1.2.4 MnM view
        • 12.1.2.4.1 Right to win
        • 12.1.2.4.2 Strategic choices
        • 12.1.2.4.3 Weaknesses & competitive threats
    • 12.1.3 MEDTRONIC PLC
      • 12.1.3.1 Business overview
      • 12.1.3.2 Products & services offered
      • 12.1.3.3 Recent developments
        • 12.1.3.3.1 Deals
      • 12.1.3.4 MnM view
        • 12.1.3.4.1 Right to win
        • 12.1.3.4.2 Strategic choices
        • 12.1.3.4.3 Weaknesses & competitive threats
    • 12.1.4 DAVITA INC.
      • 12.1.4.1 Business overview
      • 12.1.4.2 Products & services offered
      • 12.1.4.3 Recent developments
        • 12.1.4.3.1 Deals
        • 12.1.4.3.2 Expansions
      • 12.1.4.4 MnM view
        • 12.1.4.4.1 Right to win
        • 12.1.4.4.2 Strategic choices
        • 12.1.4.4.3 Weaknesses & competitive threats
    • 12.1.5 BECTON, DICKINSON AND COMPANY
      • 12.1.5.1 Business overview
      • 12.1.5.2 Products & services offered
      • 12.1.5.3 Recent developments
        • 12.1.5.3.1 Expansions
      • 12.1.5.4 MnM view
        • 12.1.5.4.1 Right to win
        • 12.1.5.4.2 Strategic choices
        • 12.1.5.4.3 Weaknesses & competitive threats
    • 12.1.6 TERUMO CORPORATION
      • 12.1.6.1 Business overview
      • 12.1.6.2 Products & services offered
      • 12.1.6.3 Recent developments
        • 12.1.6.3.1 Product approvals
        • 12.1.6.3.2 Deals
        • 12.1.6.3.3 Expansions
    • 12.1.7 UTAH MEDICAL PRODUCTS, INC.
      • 12.1.7.1 Business overview
      • 12.1.7.2 Products & services offered
    • 12.1.8 DIAVERUM AB
      • 12.1.8.1 Business overview
      • 12.1.8.2 Products & services offered
    • 12.1.9 MEDIONICS
      • 12.1.9.1 Business overview
      • 12.1.9.2 Products & services offered
    • 12.1.10 NEWSOL TECHNOLOGIES INC.
      • 12.1.10.1 Business overview
      • 12.1.10.2 Products & services offered
    • 12.1.11 APOLLO DIALYSIS PVT. LTD.
      • 12.1.11.1 Business overview
      • 12.1.11.2 Products & services offered
    • 12.1.12 U.S. RENAL CARE, INC.
      • 12.1.12.1 Business overview
      • 12.1.12.2 Products & services offered
    • 12.1.13 NORTHWEST KIDNEY CENTERS
      • 12.1.13.1 Business overview
      • 12.1.13.2 Products & services offered
      • 12.1.13.3 Recent developments
        • 12.1.13.3.1 Deals
        • 12.1.13.3.2 Expansions
    • 12.1.14 RELAVO
      • 12.1.14.1 Business overview
      • 12.1.14.2 Products & services offered
    • 12.1.15 MITRA INDUSTRIES PVT. LTD.
      • 12.1.15.1 Business overview
      • 12.1.15.2 Products & services offered
  • 12.2 OTHER PLAYERS
    • 12.2.1 JMS CO., LTD.
    • 12.2.2 AMECATH
    • 12.2.3 POLYMEDICURE
    • 12.2.4 HUAREN PHARMACEUTICAL
    • 12.2.5 AWAK TECHNOLOGIES
    • 12.2.6 INNOVATIVE RENAL CARE
    • 12.2.7 ROMSONS
    • 12.2.8 SSEM MTHEMBU MEDICAL (PTY) LTD.
    • 12.2.9 RENAX BIOMEDICAL TECHNOLOGY CO., LTD.
    • 12.2.10 ADVIN HEALTH CARE

13 APPENDIX

  • 13.1 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.2 CUSTOMIZATION OPTIONS
  • 13.3 RELATED REPORTS
  • 13.4 AUTHOR DETAILS

List of Tables

  • TABLE 1 STANDARD CURRENCY CONVERSION RATES
  • TABLE 2 NUMBER OF PEOPLE AGED 65 YEARS OR OVER, BY REGION, 2022 VS. 2050
  • TABLE 3 UTILIZATION OF KIDNEY REPLACEMENT THERAPIES (PERITONEAL DIALYSIS VS. HEMODIALYSIS)
  • TABLE 4 COST OF KIDNEY REPLACEMENT THERAPIES (2021)
  • TABLE 5 TRADE ANALYSIS OF MEDICAL DEVICE PRODUCTS
  • TABLE 6 IMPORT DATA FOR PERITONEAL DIALYSIS MACHINES, SOLUTION BAGS, CATHETERS, AND TRANSFER SETS (HS CODE 9018), BY COUNTRY, 2019-2023 (USD THOUSAND)
  • TABLE 7 EXPORT DATA FOR PERITONEAL DIALYSIS MACHINES, SOLUTION BAGS, CATHETERS AND TRANSFER SETS (HS CODE 9018), BY COUNTRY, 2019-2023 (USD THOUSAND)
  • TABLE 8 PERITONEAL DIALYSIS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 AVERAGE SELLING PRICE OF PERITONEAL DIALYSIS PRODUCTS AND CONSUMABLES, BY KEY PLAYER, 2023 (USD)
  • TABLE 15 PERITONEAL DIALYSIS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, 2024-2025
  • TABLE 16 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR PERITONEAL DIALYSIS PRODUCTS
  • TABLE 17 BUYING CRITERIA FOR PERITONEAL DIALYSIS PRODUCTS
  • TABLE 18 PERITONEAL DIALYSIS MARKET: ECOSYSTEM ANALYSIS
  • TABLE 19 CASE STUDY 1: CUSTOMIZED DIALYSIS TUBING SETS
  • TABLE 20 CASE STUDY 2: CUSTOMIZED SOFTWARE FOR AUTOMATED PERITONEAL DIALYSIS (APD) MACHINE
  • TABLE 21 PERITONEAL DIALYSIS MARKET: UNMET NEEDS
  • TABLE 22 PERITONEAL DIALYSIS MARKET: END-USER EXPECTATIONS
  • TABLE 23 PREVALENCE DATA, BY COUNTRY, 2021-2023 (PMP)
  • TABLE 24 NUMBER OF PERITONEAL DIALYSIS PATIENTS, BY REGION, 2019-2023
  • TABLE 25 NUMBER OF PERITONEAL DIALYSIS PATIENTS, BY REGION, 2024-2029
  • TABLE 26 PROCEDURE DATA FOR PERITONEAL DIALYSIS, BY COUNTRY, 2019-2023
  • TABLE 27 PROCEDURE DATA FOR PERITONEAL DIALYSIS, BY COUNTRY, 2024-2029
  • TABLE 28 PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 29 PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 30 PERITONEAL DIALYSIS PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 31 AVERAGE VOLUME OF EXCHANGE, BY REGION, 2019-2023 (MILLION LITERS)
  • TABLE 32 AVERAGE VOLUME OF EXCHANGE, BY REGION, 2024-2029 (MILLION LITERS)
  • TABLE 33 PERITONEAL DIALYSIS SOLUTION BAGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 34 PERITONEAL DIALYSIS SOLUTION BAGS MARKET, BY REGION, 2022-2029 (THOUSAND UNITS)
  • TABLE 35 PERITONEAL DIALYSIS MACHINES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 36 PERITONEAL DIALYSIS MACHINES MARKET, BY REGION, 2022-2029 (THOUSAND UNITS)
  • TABLE 37 PERITONEAL DIALYSIS CATHETERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 38 PERITONEAL DIALYSIS TRANSFER SETS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 39 OTHER PERITONEAL DIALYSIS PRODUCTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 40 PERITONEAL DIALYSIS SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 41 PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 42 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD) MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 43 AMBULATORY PERITONEAL DIALYSIS (APD) MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 44 PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 45 PERITONEAL DIALYSIS MARKET FOR END-STAGE RENAL DISEASE, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 46 PERITONEAL DIALYSIS MARKET FOR ACUTE KIDNEY INJURY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 47 PERITONEAL DIALYSIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 48 PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 49 PERITONEAL DIALYSIS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 50 PERITONEAL DIALYSIS MARKET FOR HOSPITALS & INDEPENDENT DIALYSIS CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 51 PERITONEAL DIALYSIS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 52 PERITONEAL DIALYSIS PREVALENCE DATA, BY COUNTRY, 2019-2023
  • TABLE 53 PERITONEAL DIALYSIS PREVALENCE DATA, BY COUNTRY, 2024-2029
  • TABLE 54 PERITONEAL DIALYSIS PROCEDURE DATA, BY REGION, 2019-2023 (MILLION PROCEDURES)
  • TABLE 55 PERITONEAL DIALYSIS PROCEDURE DATA, BY REGION, 2024-2029 (MILLION PROCEDURES)
  • TABLE 56 PERITONEAL DIALYSIS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 57 NORTH AMERICA: PERITONEAL DIALYSIS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 58 NORTH AMERICA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 59 NORTH AMERICA: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 60 NORTH AMERICA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 61 NORTH AMERICA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 62 NORTH AMERICA: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 63 US: MACROECONOMIC INDICATORS
  • TABLE 64 US: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 65 US: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 66 US: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 67 US: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 68 US: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 69 CANADA: MACROECONOMIC INDICATORS
  • TABLE 70 CANADA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 71 CANADA: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 72 CANADA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 73 CANADA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 74 CANADA: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 75 EUROPE: PERITONEAL DIALYSIS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 76 EUROPE: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 77 EUROPE: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 78 EUROPE: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 79 EUROPE: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 80 EUROPE: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 81 GERMANY: MACROECONOMIC INDICATORS
  • TABLE 82 GERMANY: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 83 GERMANY: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 84 GERMANY: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 85 GERMANY: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 86 GERMANY: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 87 UK: MACROECONOMIC INDICATORS
  • TABLE 88 UK: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 89 UK: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 90 UK: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 91 UK: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 92 UK: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 93 FRANCE: MACROECONOMIC INDICATORS
  • TABLE 94 FRANCE: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 95 FRANCE: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 96 FRANCE: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 97 FRANCE: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 98 FRANCE: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 99 ITALY: MACROECONOMIC INDICATORS
  • TABLE 100 ITALY: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 101 ITALY: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 102 ITALY: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 103 ITALY: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 104 ITALY: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 105 SPAIN: MACROECONOMIC INDICATORS
  • TABLE 106 SPAIN: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 107 SPAIN: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 108 SPAIN: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 109 SPAIN: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 110 SPAIN: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 111 REST OF EUROPE: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 112 REST OF EUROPE: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 113 REST OF EUROPE: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 114 REST OF EUROPE: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 115 REST OF EUROPE: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 118 ASIA PACIFIC: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 120 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 121 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 122 JAPAN: MACROECONOMIC INDICATORS
  • TABLE 123 JAPAN: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 124 JAPAN: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 125 JAPAN: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 126 JAPAN: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 127 JAPAN: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 128 CHINA: MACROECONOMIC INDICATORS
  • TABLE 129 CHINA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 130 CHINA: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 131 CHINA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 132 CHINA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 133 CHINA: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 134 INDIA: MACROECONOMIC INDICATORS
  • TABLE 135 INDIA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 136 INDIA: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 137 INDIA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 138 INDIA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 139 INDIA: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 140 AUSTRALIA: MACROECONOMIC INDICATORS
  • TABLE 141 AUSTRALIA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 142 AUSTRALIA: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 143 AUSTRALIA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 144 AUSTRALIA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 145 AUSTRALIA: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 146 SOUTH KOREA: MACROECONOMIC INDICATORS
  • TABLE 147 SOUTH KOREA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 148 SOUTH KOREA: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 149 SOUTH KOREA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 150 SOUTH KOREA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 151 SOUTH KOREA: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 152 REST OF ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 153 REST OF ASIA PACIFIC: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 154 REST OF ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 155 REST OF ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 156 REST OF ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 157 LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 158 LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 159 LATIN AMERICA: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 160 LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 161 LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 162 LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 163 BRAZIL: MACROECONOMIC INDICATORS
  • TABLE 164 BRAZIL: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 165 BRAZIL: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 166 BRAZIL: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 167 BRAZIL: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 168 BRAZIL: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 169 MEXICO: MACROECONOMIC INDICATORS
  • TABLE 170 MEXICO: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 171 MEXICO: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 172 MEXICO: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 173 MEXICO: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 174 MEXICO: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 175 REST OF LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 176 REST OF LATIN AMERICA: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 177 REST OF LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 178 REST OF LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 179 REST OF LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 180 MIDDLE EAST & AFRICA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 181 MIDDLE EAST & AFRICA: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 182 MIDDLE EAST & AFRICA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 183 MIDDLE EAST & AFRICA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 184 MIDDLE EAST & AFRICA: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 185 GCC COUNTRIES: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 186 GCC COUNTRIES: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 187 GCC COUNTRIES: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022-2029 (USD MILLION)
  • TABLE 188 GCC COUNTRIES: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 189 GCC COUNTRIES: PERITONEAL DIALYSIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 190 PERITONEAL DIALYSIS MARKET: DEGREE OF COMPETITION
  • TABLE 191 PERITONEAL DIALYSIS MARKET: OFFERING FOOTPRINT
  • TABLE 192 PERITONEAL DIALYSIS MARKET: MODALITY FOOTPRINT
  • TABLE 193 PERITONEAL DIALYSIS MARKET: DISEASE INDICATION FOOTPRINT
  • TABLE 194 PERITONEAL DIALYSIS MARKET: END-USER FOOTPRINT
  • TABLE 195 PERITONEAL DIALYSIS MARKET: REGION FOOTPRINT
  • TABLE 196 PERITONEAL DIALYSIS MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
  • TABLE 197 PERITONEAL DIALYSIS MARKET: COMPETITIVE BENCHMARKING OF KEY START-UP/SME PLAYERS REGION FOOTPRINT
  • TABLE 198 PERITONEAL DIALYSIS MARKET: PRODUCT APPROVALS (JANUARY 2021- SEPTEMBER 2024)
  • TABLE 199 PERITONEAL DIALYSIS MARKET: DEALS, JANUARY 2020-SEPTEMBER 2024
  • TABLE 200 PERITONEAL DIALYSIS MARKET: EXPANSIONS, JANUARY 2020-SEPTEMBER 2024
  • TABLE 201 FRESENIUS MEDICAL CARE AG: COMPANY OVERVIEW
  • TABLE 202 FRESENIUS MEDICAL CARE AG: PRODUCTS & SERVICES OFFERED
  • TABLE 203 FRESENIUS MEDICAL CARE AG: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 204 BAXTER INTERNATIONAL INC.: COMPANY OVERVIEW
  • TABLE 205 BAXTER INTERNATIONAL INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 206 BAXTER INTERNATIONAL INC.: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 207 MEDTRONIC PLC: COMPANY OVERVIEW
  • TABLE 208 MEDTRONIC PLC: PRODUCTS & SERVICES OFFERED
  • TABLE 209 MEDTRONIC PLC: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 210 DAVITA INC.: COMPANY OVERVIEW
  • TABLE 211 DAVITA INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 212 DAVITA INC.: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 213 DAVITA INC.: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 214 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 215 BECTON, DICKINSON AND COMPANY: PRODUCTS & SERVICES OFFERED
  • TABLE 216 BECTON, DICKINSON AND COMPANY: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 217 TERUMO CORPORATION: COMPANY OVERVIEW
  • TABLE 218 TERUMO CORPORATION: PRODUCTS & SERVICES OFFERED
  • TABLE 219 TERUMO CORPORATION: PRODUCT APPROVALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 220 TERUMO CORPORATION: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 221 TERUMO CORPORATION: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 222 UTAH MEDICAL PRODUCTS, INC.: BUSINESS OVERVIEW
  • TABLE 223 UTAH MEDICAL PRODUCTS, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 224 DIAVERUM AB: COMPANY OVERVIEW
  • TABLE 225 DIAVERUM AB: PRODUCTS & SERVICES OFFERED
  • TABLE 226 MEDIONICS: BUSINESS OVERVIEW
  • TABLE 227 MEDIONICS: PRODUCTS & SERVICES OFFERED
  • TABLE 228 NEWSOL TECHNOLOGIES INC.: COMPANY OVERVIEW
  • TABLE 229 NEWSOL TECHNOLOGIES INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 230 APOLLO DIALYSIS PVT. LTD.: BUSINESS OVERVIEW
  • TABLE 231 APOLLO DIALYSIS PVT. LTD.: PRODUCTS & SERVICES OFFERED
  • TABLE 232 U.S. RENAL CARE, INC.: BUSINESS OVERVIEW
  • TABLE 233 U.S. RENAL CARE, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 234 NORTHWEST KIDNEY CENTERS: COMPANY OVERVIEW
  • TABLE 235 NORTHWEST KIDNEY CENTERS: PRODUCTS & SERVICES OFFERED
  • TABLE 236 NORTHWEST KIDNEY CENTERS: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 237 NORTHWEST KIDNEY CENTERS: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 238 RELAVO: COMPANY OVERVIEW
  • TABLE 239 RELAVO: PRODUCTS & SERVICES OFFERED
  • TABLE 240 MITRA INDUSTRIES PVT. LTD.: BUSINESS OVERVIEW
  • TABLE 241 MITRA INDUSTRIES PVT. LTD.: PRODUCTS & SERVICES OFFERED

List of Figures

  • FIGURE 1 PERITONEAL DIALYSIS MARKET: SEGMENTS COVERED
  • FIGURE 2 RESEARCH DESIGN: PERITONEAL DIALYSIS MARKET
  • FIGURE 3 INDICATIVE LIST OF SECONDARY SOURCES
  • FIGURE 4 LIST OF KEY PRIMARY SOURCES
  • FIGURE 5 KEY INDUSTRY INSIGHTS
  • FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 8 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 9 REVENUE SHARE ANALYSIS ILLUSTRATION
  • FIGURE 10 SUPPLY-SIDE MARKET SIZE ESTIMATION: PERITONEAL DIALYSIS MARKET (2023)
  • FIGURE 11 ESTIMATION OF PERITONEAL DIALYSIS PROCEDURES, BY COUNTRY/REGION
  • FIGURE 12 MARKET SIZE ESTIMATION: PERITONEAL DIALYSIS MARKET, BY PRODUCT UTILIZATION METHODOLOGY
  • FIGURE 13 MARKET SIZE ESTIMATION: PERITONEAL DIALYSIS SERVICES MARKET, BY REVENUE MAPPING METHODOLOGY
  • FIGURE 14 PERITONEAL DIALYSIS: AVERAGE VOLUME EXCHANGE ESTIMATION MODEL
  • FIGURE 15 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024-2029)
  • FIGURE 16 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 17 DATA TRIANGULATION METHODOLOGY
  • FIGURE 18 PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
  • FIGURE 19 PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 20 PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024 VS. 2029 (USD MILLION)
  • FIGURE 21 PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 22 PERITONEAL DIALYSIS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 23 GEOGRAPHIC SNAPSHOT: PERITONEAL DIALYSIS MARKET
  • FIGURE 24 INCREASING PREVALENCE OF ESRD TO DRIVE MARKET GROWTH
  • FIGURE 25 JAPAN ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023
  • FIGURE 26 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 27 NORTH AMERICA TO CONTINUE TO DOMINATE PERITONEAL DIALYSIS MARKET DURING FORECAST PERIOD
  • FIGURE 28 DEVELOPING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
  • FIGURE 29 PERITONEAL DIALYSIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 30 CANADA: NUMBER OF END-STAGE RENAL DISEASE PATIENTS, BY AGE GROUP (2022)
  • FIGURE 31 US: REPORTED CAUSES OF END-STAGE RENAL DISEASES, 2023
  • FIGURE 32 INCIDENCE OF TREATED END-STAGE RENAL DISEASE, 2021
  • FIGURE 33 SHORTAGES OF NEPHROLOGISTS IN LOW-INCOME AND LOWER-MIDDLE-INCOME COUNTRIES (LLMICS)
  • FIGURE 34 PERITONEAL DIALYSIS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 35 PERITONEAL DIALYSIS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 36 PERITONEAL DIALYSIS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 37 PATENT PUBLICATION TRENDS (2014-2024)
  • FIGURE 38 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR PERITONEAL DIALYSIS PATENTS (JANUARY 2014-SEPTEMBER 2024)
  • FIGURE 39 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PERITONEAL DIALYSIS PRODUCTS
  • FIGURE 40 KEY BUYING CRITERIA FOR PERITONEAL DIALYSIS PRODUCTS
  • FIGURE 41 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET OVERVIEW
  • FIGURE 42 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET OVERVIEW
  • FIGURE 43 KEY FEATURES OF GENERATIVE AI IN PERITONEAL DIALYSIS MARKET
  • FIGURE 44 PERITONEAL DIALYSIS MARKET: TRENDS/DISRUPTIONS AFFECTING CUSTOMERS' BUSINESSES
  • FIGURE 45 NUMBER OF DEALS & FUNDING ACTIVITY IN PERITONEAL DIALYSIS MARKET, 2019-2023 (USD MILLION)
  • FIGURE 46 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019-2023
  • FIGURE 47 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2019-2023 (USD MILLION)
  • FIGURE 48 NORTH AMERICA: PERITONEAL DIALYSIS MARKET SNAPSHOT
  • FIGURE 49 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET SNAPSHOT
  • FIGURE 50 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PRODUCT & SERVICE COMPANIES
  • FIGURE 51 REVENUE ANALYSIS OF TOP THREE PLAYERS IN PERITONEAL DIALYSIS MARKET (2019-2023)
  • FIGURE 52 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PERITONEAL DIALYSIS MARKET (2023)
  • FIGURE 53 PERITONEAL DIALYSIS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 54 PERITONEAL DIALYSIS MARKET: COMPANY FOOTPRINT
  • FIGURE 55 PERITONEAL DIALYSIS MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
  • FIGURE 56 EV/EBITDA OF KEY VENDORS
  • FIGURE 57 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 58 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 59 R&D EXPENDITURE OF KEY PLAYERS (2022 VS. 2023)
  • FIGURE 60 FRESENIUS MEDICAL CARE AG: COMPANY SNAPSHOT (2023)
  • FIGURE 61 BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 62 MEDTRONIC PLC: COMPANY SNAPSHOT (2023)
  • FIGURE 63 DAVITA INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 64 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
  • FIGURE 65 TERUMO CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 66 UTAH MEDICAL PRODUCTS, INC.: COMPANY SNAPSHOT (2023)